Rheumatoid arthritis (RA) new drug! AbbVie oral JAK inhibitor Rinvoq head-to-head Phase III efficacy beats Orencia (Abassup)!
Last Update: 2020-06-17
Search more information of high quality chemicals, good prices and reliable suppliers, visit
, June 08, 2020 /PRNewswire/ -- AbbVie,Biovalley
BIOON/-- AbbVie recently announced new clinical trial data on the treatment of therheumatoid arthritis(RA) Phase III select-
at the 2020 European Union for Rheumatology (EULAR) ElectronicConferencethe study was conducted in adult patients with moderate to severe RA who had previously had inadequate responses to anti-rheumatic drugs (bDMARD) for biological diseasemodifications or intoleranceThe results showed that the study reached the main endpoint: Rinvoq and the peri-esquiver injection drug Orencia (abatacept, abasse, intravenous infusion) were non-essential in terms of baseline changes in the disease activity score 28 C-CRP for the 12th week of treatmentIn addition, the study reached several key secondary endpoints: Rinvoq outperformed Orencia in terms of changes in DAS28-CRP from baseline in week 12 of treatment, and patientproportion sourcing in week 12 of clinical remission (with DAS28-CRP 2.6)SELECT-CHOICE is the sixth and final Phase III study of select RAclinical trialsprojectRinvoq is an optional and reversible JAK inhibitor discovered and developed by AbbVie and has been approved for the treatment of moderate to severe active RA adult patients with inadequate response or intolerance to one or more DMARDsin thesestudies, Rinvoq reached both primary (non-ineffective) and secondary (excellent) endpoints: in the 12th week of treatment, the Rinvoq treatment group DAS28-CRP changed to -2.52 compared to the baseline, while the Orencia group changed to -2.00 In addition, in the 12th week of treatment 30% of the patients in the Rinvoq treatment group achieved clinical remission (DAS28-CRP 2.6), compared with 13% of the Orencia group (p 0.001) In addition, in the 12th week of treatment, the Response rate of ACR20/50/70 in the Rinvoq group was higher than in the Orencia group (76/46/22% vs 66/34/14%, nominal p 0.05, respectively) During the 24-week period, disease activity and mitigation rates improved In this study, rinvoq (15 mg) was consistent with previously reported RA studies and no new security risks were identified "Despite significant progress in RA therapy, about 70 percent of patients still do not achieve clinical remission through existing treatments," said Dr Michael Severino, vice president and president of AbbVie We are pleased with these results, which complement the growing evidence that Rinvoq may provide a better opportunity for more adult RA patients to achieve clinical remission, including those who have previously failed to receive a biologic "These data show that Rinvoq is better than Orencia in terms of the proportion of patients who receive remission," said Professor Andrea Rubbert Roth, MD, deputy director of rheumatology at st Gallen's Hospital in Switzerland, The SELECT-CHOICE study represents the first head-to-head study of Ra patients with bDMARD treatment that compared Rinvoq with another different bDMARD Such research is very important for day-to-day decision-making practices "
Rinvoq's active drug ingredient is upadacitinib, an oral selective and reversible JAK1 inhibitor found and developed by AbbVie, which is being developed to treat several immuno-mediated inflammatory diseases JAK1 is a kinase that plays a key role in the pathophysiological process esccophysiology of a variety of inflammatory diseases August 2019, Rinvoq was the world's first to treat adult patients with moderate to severe active arthriti
s (RA) who have inadequate or intolerable responsetos to methotrexate (MTX) In December 2019, Rinvoq was approved by the European Union for the treatment of adult patients with moderate to severe RA who do not respond to or tolerate an inadequate response to one or more disease-modified anti-rheumatic drugs (DMARD) In RA, the approved dose of Rinvoq is 15 mg currently, A Phase III clinical study of Rinvoq's treatment of psoriasis arthritis (PsA), RA, mid-axis spinal arthritis (axSpA), Crohn's disease (CD), teriotorthemy (AD), ulcerative colitis (UC), and cytomegaloartis (GCA) is under way just recently, AbbVie announced that it had submitted a new indication application for Rinvoq (upadacitinib, 15mg, daily) in the United States and the European Union for the treatment of active PsA adult patients the industry is very bullish on Rinvoq's business prospects In a previous report, Evaluate Pharma, a pharmaceutical market research firm, predicted that Rinvoq's global sales would reach $2.57 billion in 2024, making it the world's fifth-best-selling anti-rheumatic drug (BioValleyBioon.com) original source: AbbVie Presents Data Show RinvoQ ™ (upadacitinib) Meets Primary and Key Secondary S Eendpoint in Phase 3 Head-to-Head Study Versus OrenCIA (abatacept) in Rheumoid Arthritis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.